BioVie Inc. and iRemedy Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / March 24, 2023 / RedChip Companies will feature BioVie Inc. (NASDAQ:BIVI) in upcoming interviews on The RedChip Money Report® airing on Bloomberg TV on March 25 at 7 p.m. Eastern Time (ET). The program reaches approximately 73 million households in the U.S. BioVie is a clinical-stage company focused on innovative drug therapies for neurological disorders and liver disease. Its key drug candidates include NE3107 for Alzheimer's and Parkinson's diseases, and BIV201 for liver cirrhosis, both under ongoing clinical evaluations. Watch the interviews at BioVie Interview Access.
- BioVie is featured on The RedChip Money Report, increasing visibility.
- Ongoing clinical trials for NE3107 and BIV201 may lead to significant advancements in treatment options.
- None.
ORLANDO, FL / ACCESSWIRE / March 24, 2023 / RedChip Companies will air new interviews with BioVie Inc. (NASDAQ:BIVI) and iRemedy on The RedChip Money Report® on Bloomberg TV, this Saturday, March 25, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
- BioVie Inc. (Nasdaq: BIVI): https://www.biviinfo.com/interview_access
- iRemedy: https://iremedyinfo.com/interview_access
About The RedChip Money Report®
The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™. "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
About BioVie Inc.
BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer's and Parkinson's diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer's Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's. A Phase 2 study of NE3107 in Parkinson's disease (NCT05083260) has completed, and topline data released in December 2022, showed clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2b study for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http://www.bioviepharma.com/.
About iRemedy
iRemedy is an advanced, technology-driven healthcare and medical products distributor actively engaged in disrupting and positively transforming the medical supply chain industry through the creation and support of an open, fair, and fully transparent hyper marketplace for the sale and purchase of medical and healthcare supplies to government agencies, care providers, and consumers.
By leveraging groundbreaking technological innovation paired with the ease and convenience of ecommerce, iRemedy is trusted and relied upon to provide its customers with access to over one million (and growing) high-quality products.
Products include disposable medical supplies, medical devices, durable medical equipment, surgical equipment, health monitoring devices, wound care products, dental equipment and supplies, retail healthcare products, medical and surgical apparel, and office supplies.
For more information about the Company, please visit https://iremedy.com/.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Contact:
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
info@redchip.com
SOURCE: RedChip
View source version on accesswire.com:
https://www.accesswire.com/745609/BioVie-Inc-and-iRemedy-Interviews-to-Air-on-Bloomberg-US-on-the-RedChip-Money-ReportR
FAQ
When will BioVie Inc. appear on Bloomberg TV?
What is the focus of BioVie Inc.'s drug candidates?
What are the key drug candidates being developed by BioVie Inc.?
How can I access the interviews with BioVie Inc.?
